Statins increase cytochrome P450 4F3-mediated eicosanoids production in human liver cells: A PXR dependent mechanism

Biochemical Pharmacology

Volumn 84, Issue 4, 2012, Pages 571-579

  Plée Gautier, Emmanuelle ^a   Antoun, Joseph ^a,b   Goulitquer, Sophie ^a,c   Le Jossic Corcos, Catherine ^a   Simon, Brigitte ^a   Amet, Yolande ^a   Salaün, Jean Pierre ^a   Corcos, Laurent ^a  

^a FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c CNRS   (France)

Author keywords

CYP4F3; Fatty acids; HETE; PXR; Statin

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ARACHIDONIC ACID; CHOLESTEROL; CYTOCHROME P450; CYTOCHROME P450 4F3B; FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; MESSENGER RNA; MEVALONIC ACID; MEVINOLIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PREGNANE X RECEPTOR; SMALL INTERFERING RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN; UNCLASSIFIED DRUG;

ARACHIDONIC ACID METABOLISM; ARTICLE; CELL DIFFERENTIATION; GENE CONTROL; GENE EXPRESSION; HEPATOMA CELL; HUMAN; HUMAN CELL; LIPID METABOLISM; LIVER CELL; PRIORITY JOURNAL; TUMOR CELL LINE;

APOLIPOPROTEIN A-I; CELL LINE, TUMOR; CHOLESTEROL; COENZYME A LIGASES; CYTOCHROME P-450 ENZYME SYSTEM; EICOSANOIDS; ENZYME INDUCTION; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; LOVASTATIN; MEVALONIC ACID; PROMOTER REGIONS, GENETIC; RECEPTORS, STEROID; RNA, MESSENGER; RNA, SMALL INTERFERING; STEROL REGULATORY ELEMENT BINDING PROTEINS;

EID: 84864116695     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.05.012     Document Type: Article

References (59)

1. R.W. Estabrook A passion for P450s (rememberances of the early history of research on cytochrome P450) Drug Metab Dispos 31 12 2003 1461 1473
2. A. Kalsotra, and H.W. Strobel Cytochrome P450 4F subfamily: at the crossroads of eicosanoid and drug metabolism Pharmacol Ther 112 3 2006 589 611
3. Corcos L, Lucas D, Le Jossic-Corcos C, Dréano Y, Simon B, Plée-Gautier E, Amet Y, Salaün JP. Human Cytochrome P450 4F3: structure, functions and prospects. Drug Metab Drug Interact, in press.
4. M. Fer, L. Corcos, Y. Dreano, E. Plee-Gautier, J.P. Salaun, and F. Berthou Cytochromes P450 from family 4 are the main omega hydroxylating enzymes in humans: CYP4F3B is the prominent player in PUFA metabolism J Lipid Res 49 11 2008 2379 2389
5. J. Antoun, S. Goulitquer, Y. Amet, Y. Dreano, J.P. Salaun, and L. Corcos CYP4F3B is induced by PGA1 in human liver cells: a regulation of the 20-HETE synthesis J Lipid Res 49 10 2008 2135 2141
6. C.J. Liang, C.P. Tseng, C.M. Yang, and Y.H. Ma 20-Hydroxyeicosatetraenoic acid inhibits ATP-induced COX-2 expression via peroxisome proliferator activator receptor-alpha in vascular smooth muscle cells Br J Pharmacol 163 4 2011 815 825
7. D. Sacerdoti, A. Gatta, and J.C. McGiff Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology Prostaglandins Other Lipid Mediat 72 1-2 2003 51 71
8. R.M. Gu, L. Yang, Y. Zhang, L. Wang, S. Kong, and C. Zhang CYP-omega-hydroxylation-dependent metabolites of arachidonic acid inhibit the basolateral 10 pS chloride channel in the rat thick ascending limb Kidney Int 76 8 2009 949 956
9. T. Akbulut, K.R. Regner, R.J. Roman, E.D. Avner, J.R. Falck, and F. Park 20-HETE activates the Raf/MEK/ERK pathway in renal epithelial cells through EGFR- and c-Src-dependent mechanisms Am J Physiol Renal Physiol 297 3 2009 F662 F670
10. E.G. Schuetz, J.D. Schuetz, S.C. Strom, M.T. Thompson, R.A. Fisher, and D.T. Molowa Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes Hepatology 18 5 1993 1254 1262
11. M.H. Hsu, U. Savas, K.J. Griffin, and E.F. Johnson Regulation of human cytochrome P450 4F2 expression by sterol regulatory element-binding protein and lovastatin J Biol Chem 282 8 2007 5225 5236
12. M.A. Willrich, M.H. Hirata, and R.D. Hirata Statin regulation of CYP3A4 and CYP3A5 expression Pharmacogenomics 10 6 2009 1017 1024
13. L. Corcos, and D. Lagadic-Gossmann Gene induction by phenobarbital: an update on an old question that receives key novel answers Pharmacol Toxicol 89 3 2001 113 122
14. T. Wada, J. Gao, and W. Xie PXR and CAR in energy metabolism Trends Endocrinol Metab 20 6 2009 273 279
15. A. Moreau, M.J. Vilarem, P. Maurel, and J.M. Pascussi Xenoreceptors CAR and PXR activation and consequences on lipid metabolism, glucose homeostasis, and inflammatory response Mol Pharmacol 5 1 2008 35 41
16. D.J. Mangelsdorf, and R.M. Evans The RXR heterodimers and orphan receptors Cell 83 6 1995 841 850
17. V. Le Quere, E. Plee-Gautier, P. Potin, S. Madec, and J.P. Salaun Human CYP4F3s are the main catalysts in the oxidation of fatty acid epoxides J Lipid Res 45 8 2004 1446 1458
18. P. Gripon, S. Rumin, S. Urban, J. Le Seyec, D. Glaise, and I. Cannie Infection of a human hepatoma cell line by hepatitis B virus Proc Natl Acad Sci USA 99 24 2002 15655 15660
19. J. Antoun, Y. Amet, B. Simon, Y. Dreano, A. Corlu, and L. Corcos CYP4A11 is repressed by retinoic acid in human liver cells FEBS Lett 580 14 2006 3361 3367
20. K. Nithipatikom, R.F. DiCamelli, S. Kohler, R.J. Gumina, J.R. Falck, and W.B. Campbell Determination of cytochrome P450 metabolites of arachidonic acid in coronary venous plasma during ischemia and reperfusion in dogs Anal Biochem 292 1 2001 115 124
21. L. Gibot, J. Follet, J.P. Metges, P. Auvray, B. Simon, and L. Corcos Human caspase 7 is positively controlled by SREBP-1 and SREBP-2 Biochem J 420 3 2009 473 483
22. K. Howe, F. Sanat, A.E. Thumser, T. Coleman, and N. Plant The statin class of HMG-CoA reductase inhibitors demonstrate differential activation of the nuclear receptors PXR, CAR and FXR, as well as their downstream target genes Xenobiotica 41 7 2011 519 529
23. J. Rossi, L. Rouleau, A. Emmott, J.C. Tardif, and R.L. Leask Laminar shear stress prevents simvastatin-induced adhesion molecule expression in cytokine activated endothelial cells Eur J Pharmacol 649 1-3 2010 268 276
24. E. Logette, C. Le Jossic-Corcos, D. Masson, S. Solier, A. Sequeira-Legrand, and I. Dugail Caspase-2, a novel lipid sensor under the control of sterol regulatory element binding protein 2 Mol Cell Biol 25 21 2005 9621 9631
25. G.J. Botma, D. van Deursen, D. Vieira, M. van Hoek, H. Jansen, and A.J. Verhoeven Sterol-regulatory-element binding protein inhibits upstream stimulatory factor-stimulated hepatic lipase gene expression Atherosclerosis 179 1 2005 61 67
26. R.A. DeBose-Boyd, J. Ou, J.L. Goldstein, and M.S. Brown Expression of sterol regulatory element-binding protein 1c (SREBP-1c) mRNA in rat hepatoma cells requires endogenous LXR ligands Proc Natl Acad Sci USA 98 4 2001 1477 1482
27. G. Dubuc, A. Chamberland, H. Wassef, J. Davignon, N.G. Seidah, and L. Bernier Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia Arterioscler Thromb Vasc Biol 24 8 2004 1454 1459
28. C. Mascaro, J.A. Ortiz, M.M. Ramos, D. Haro, and F.G. Hegardt Sterol regulatory element binding protein-mediated effect of fluvastatin on cytosolic 3-hydroxy-3-methylglutaryl-coenzyme A synthase transcription Arch Biochem Biophys 374 2 2000 286 292
29. L. Xu, Q. Bai, D. Rodriguez-Agudo, P.B. Hylemon, D.M. Heuman, and W.M. Pandak Regulation of hepatocyte lipid metabolism and inflammatory response by 25-hydroxycholesterol and 25-hydroxycholesterol-3-sulfate Lipids 45 9 2010 821 832
30. S. Ren, X. Li, D. Rodriguez-Agudo, G. Gil, P. Hylemon, and W.M. Pandak Sulfated oxysterol, 25HC3S, is a potent regulator of lipid metabolism in human hepatocytes Biochem Biophys Res Commun 360 4 2007 802 808
31. Y. Kawabe, R. Sato, A. Matsumoto, M. Honda, Y. Wada, and Y. Yazaki Regulation of fatty acid synthase expression by cholesterol in human cultured cells Biochem Biophys Res Commun 219 2 1996 515 520
32. S.P. Tam, L. Mok, G. Chimini, M. Vasa, and R.G. Deeley ABCA1 mediates high-affinity uptake of 25-hydroxycholesterol by membrane vesicles and rapid efflux of oxysterol by intact cells Am J Physiol Cell Physiol 291 3 2006 C490 C502
33. T.A. Kocarek, and A.B. Reddy Regulation of cytochrome P450 expression by inhibitors of hydroxymethylglutaryl-coenzyme A reductase in primary cultured rat hepatocytes and in rat liver Drug Metab Dispos 24 11 1996 1197 1204
34. D.M. Feidt, K. Klein, U. Hofmann, S. Riedmaier, D. Knobeloch, and W.E. Thasler Profiling induction of cytochrome P450 enzyme activity by statins using A new LC-MS/MS cocktail assay in human hepatocytes Drug Metab Dispos 39 9 2010 1589 1597
35. A. Guillouzo, A. Corlu, C. Aninat, D. Glaise, F. Morel, and C. Guguen-Guillouzo The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics Chem Biol Interact 168 2006 66 73
36. M. Lubberstedt, U. Muller-Vieira, M. Mayer, K.M. Biemel, F. Knospel, and D. Knobeloch HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro J Pharmacol Toxicol Methods 63 1 2011 59 68
37. K.P. Kanebratt, and T.B. Andersson Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies Drug Metab Dispos 36 7 2008 1444 1452
38. S. Antherieu, C. Chesne, R. Li, S. Camus, A. Lahoz, and L. Picazo Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells Drug Metab Dispos 38 3 2010 516 525
39. H.H. Gerets, K. Tilmant, B. Gerin, H. Chanteux, B.O. Depelchin, and S. Dhalluin Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins Cell Biol Toxicol 28 2 2012 69 87
40. C.B. Lambert, C. Spire, N. Claude, and A. Guillouzo Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells Toxicol Appl Pharmacol 234 3 2009 345 360
41. M. Turpeinen, A. Tolonen, C. Chesne, A. Guillouzo, J. Uusitalo, and O. Pelkonen Functional expression, inhibition and induction of CYP enzymes in HepaRG cells Toxicol In Vitro 23 4 2009 748 753
42. A. Guillouzo, A. Corlu, C. Aninat, D. Glaise, F. Morel, and C. Guguen-Guillouzo The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics Chem Biol Interact 168 1 2007 66 73
43. S.A. Holstein, H.R. Knapp, G.H. Clamon, D.J. Murry, and R.J. Hohl Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies Cancer Chemother Pharmacol 57 2 2006 155 164
44. A. Thibault, D. Samid, A.C. Tompkins, W.D. Figg, M.R. Cooper, and R.J. Hohl Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer Clin Cancer Res 2 3 1996 483 491
45. V.Y. Ng, Y. Huang, L.M. Reddy, J.R. Falck, E.T. Lin, and D.L. Kroetz Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha (PPAR{alpha}) Drug Metab Dispos 35 7 2007 1126 1134
46. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS) Circulation 97 15 1998 1440 1445
47. R. Paumelle, and B. Staels Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms Trends Cardiovasc Med 18 3 2008 73 78
48. T. Ravingerova, A. Adameova, T. Kelly, E. Antonopoulou, D. Pancza, and M. Ondrejcakova Changes in PPAR gene expression and myocardial tolerance to ischaemia: relevance to pleiotropic effects of statins Can J Physiol Pharmacol 87 12 2009 1028 1036
49. M. Yano, T. Matsumura, T. Senokuchi, N. Ishii, Y. Murata, and K. Taketa Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages Circ Res 100 10 2007 1442 1451
50. R. Paumelle, C. Blanquart, O. Briand, O. Barbier, C. Duhem, and G. Woerly Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway Circ Res 98 3 2006 361 369
51. C. Bertrand-Thiebault, C. Masson, G. Siest, A.M. Batt, and S. Visvikis-Siest Effect of HMGCoA reductase inhibitors on cytochrome P450 expression in endothelial cell line J Cardiovasc Pharmacol 49 5 2007 306 315
52. M. Hafner, P. Juvan, T. Rezen, K. Monostory, J.M. Pascussi, and D. Rozman The human primary hepatocyte transcriptome reveals novel insights into atorvastatin and rosuvastatin action Pharmacogenet Genomics 21 11 2011 741 750
53. J. Raucy, L. Warfe, M.F. Yueh, and S.W. Allen A cell-based reporter gene assay for determining induction of CYP3A4 in a high-volume system J Pharmacol Exp Ther 303 1 2002 412 423
54. G. Qiu, and J.S. Hill Atorvastatin inhibits ABCA1 expression and cholesterol efflux in THP-1 macrophages by an LXR-dependent pathway J Cardiovasc Pharmacol 51 4 2008 388 395
55. P. Christmas, S.R. Ursino, J.W. Fox, and R.J. Soberman Expression of the CYP4F3 gene. Tissue-specific splicing and alternative promoters generate high and low K(m) forms of leukotriene B(4) omega-hydroxylase J Biol Chem 274 30 1999 21191 21199
56. M. Wagner, E. Halilbasic, H.U. Marschall, G. Zollner, P. Fickert, and C. Langner CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice Hepatology 42 2 2005 420 430
57. K. Monostory, J.M. Pascussi, P. Szabo, M. Temesvari, K. Kohalmy, and J. Acimovic Drug interaction potential of 2-((3,4-dichlorophenethyl)(propyl)amino)- 1-(pyridin-3-yl)ethanol (LK-935), the novel nonstatin-type cholesterol-lowering agent Drug Metab Dispos 37 2 2009 375 385
58. Y.C. Lin, J.H. Lin, C.W. Chou, Y.F. Chang, S.H. Yeh, and C.C. Chen Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2 Cancer Res 68 7 2008 2375 2383
59. K. Lichti-Kaiser, C. Xu, and J.L. Staudinger Cyclic AMP-dependent protein kinase signaling modulates pregnane × receptor activity in a species-specific manner J Biol Chem 284 11 2009 6639 6649